Drug Profile
VPI 2690B
Alternative Names: VPI-2690BLatest Information Update: 24 Sep 2020
Price :
$50
*
At a glance
- Originator University of North Carolina
- Developer Vascular Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor-I receptor antagonists; Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic nephropathies
Most Recent Events
- 24 Sep 2020 Phase II development is ongoing for Diabetic nephropathies in Puerto Rico and USA (Vascular Pharmaceuticals website, September 2020)
- 01 Mar 2017 Vascular Pharmaceuticals completes a phase II trial in Diabetic nephropathies in USA and Puerto Rico (NCT02251067)
- 09 Dec 2016 VPI 2690B is still in phase II trials for Diabetic nephropathies in USA (NCT02251067)